Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-labetuzumab in Refractory Pancreatic Cancer
NCT00041639Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2000
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 labetuzumab in pancreatic carcinoma, sponsored by Gilead Sciences. Primary endpoints: Safety and Adverse Events and Maximum Tolerated Dose. Started Jan 2000; status: completed.
02
Drugs
yttrium-90 labetuzumab
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT00041639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041639.